NEUP (Neuphoria Therapeutics) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Neuphoria Therapeutics Days Payable?

Neuphoria Therapeutics's average Accounts Payable for the three months ended in Dec. 2024 was $1.43 Mil. Neuphoria Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Neuphoria Therapeutics's Days Payable or its related term are showing as below:

NEUP's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 124.08
* Ranked among companies with meaningful Days Payable only.

Neuphoria Therapeutics's Days Payable stayed the same from Sep. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Neuphoria Therapeutics Days Payable Historical Data

The historical data trend for Neuphoria Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuphoria Therapeutics Days Payable Chart

Neuphoria Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Days Payable

Get a 7-Day Free Trial

Neuphoria Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Neuphoria Therapeutics's Days Payable

For the Biotechnology subindustry, Neuphoria Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuphoria Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Neuphoria Therapeutics's Days Payable falls into.

Save Embed

;

Save Embed

;

Neuphoria Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Neuphoria Therapeutics's Days Payable for the fiscal year that ended in Jun. 2024 is calculated as

	Days Payable (A: Jun. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2023 )	+	Accounts Payable (A: Jun. 2024 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2024 )	*	Days in Period
=	( (1.439	+	2.244)	/	2 )	/	0	*	365
=	1.8415					/	0	*	365
=	N/A

Neuphoria Therapeutics's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (1.326	+	1.531)	/	2 )	/	0	*	365 / 4
=	1.4285					/	0	*	365 / 4
=	N/A

Neuphoria Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Neuphoria Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuphoria Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuphoria Therapeutics Inc (NAS:NEUP) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Summit Dr, Burlington, MA, USA, 01803

Website

https://www.bionomics.com.au

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.